Back to Search
Start Over
Targeting malignant mitochondria with therapeutic peptides.
- Source :
-
Therapeutic delivery [Ther Deliv] 2012 Aug; Vol. 3 (8), pp. 961-79. - Publication Year :
- 2012
-
Abstract
- The current status of peptides that target the mitochondria in the context of cancer is the focus of this review. Chemotherapy and radiotherapy used to kill tumor cells are principally mediated by the process of apoptosis that is governed by the mitochondria. The failure of anticancer therapy often resides at the level of the mitochondria. Therefore, the mitochondrion is a key pharmacological target in cancer due to many of the differences that arise between malignant and healthy cells at the level of this ubiquitous organelle. Additionally, targeting the characteristics of malignant mitochondira often rely on disruption of protein--protein interactions that are not generally amenable to small molecules. We discuss anticancer peptides that intersect with pathological changes in the mitochondrion.
- Subjects :
- Antineoplastic Agents therapeutic use
Apoptosis drug effects
Humans
Mitochondria metabolism
Models, Biological
Peptides therapeutic use
Signal Transduction drug effects
Antineoplastic Agents administration & dosage
Drug Delivery Systems methods
Mitochondria drug effects
Neoplasms drug therapy
Peptides administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 2041-5990
- Volume :
- 3
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Therapeutic delivery
- Publication Type :
- Academic Journal
- Accession number :
- 22946430
- Full Text :
- https://doi.org/10.4155/tde.12.75